
Janssen’s antidepressant nasal spray is not welcome in Denmark.
The Danish Medicines Council has once again turned up its nose at Spravato (esketamine) as a relevant treatment choice for treatment-resistant depression in combination with SNRIs (serotonin and norepinephrine reuptake inhibitors) or SSRIs (selective serotonin reuptake inhibitors).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app